Axsome Therapeutics, Inc. (AXSM)
137.01
-4.68
(-3.30%)
USD |
NASDAQ |
Nov 16, 16:00
135.01
-2.00
(-1.46%)
After-Hours: 06:47
Axsome Therapeutics EPS Diluted (Quarterly) : -0.2455 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.2455 |
| June 30, 2026 | -0.9906 |
| March 31, 2026 | -1.261 |
| December 31, 2025 | -0.5641 |
| September 30, 2025 | -0.9442 |
| June 30, 2025 | -0.9703 |
| March 31, 2025 | -1.216 |
| December 31, 2024 | -1.543 |
| September 30, 2024 | -1.342 |
| June 30, 2024 | -1.668 |
| March 31, 2024 | -1.442 |
| December 31, 2023 | -2.084 |
| September 30, 2023 | -1.320 |
| June 30, 2023 | -1.538 |
| March 31, 2023 | -0.2578 |
| December 31, 2022 | -1.410 |
| September 30, 2022 | -1.075 |
| June 30, 2022 | -1.060 |
| March 31, 2022 | -1.034 |
| December 31, 2021 | -0.8997 |
| September 30, 2021 | -0.9257 |
| June 30, 2021 | -0.8587 |
| Date | Value |
|---|---|
| March 31, 2021 | -0.7817 |
| December 31, 2020 | -0.7808 |
| September 30, 2020 | -0.6144 |
| June 30, 2020 | -0.494 |
| March 31, 2020 | -0.8765 |
| December 31, 2019 | -0.7137 |
| September 30, 2019 | -0.5555 |
| June 30, 2019 | -0.4072 |
| March 31, 2019 | -0.3219 |
| December 31, 2018 | -0.3212 |
| September 30, 2018 | -0.3146 |
| June 30, 2018 | -0.3211 |
| March 31, 2018 | -0.1884 |
| December 31, 2017 | -0.31 |
| September 30, 2017 | -0.27 |
| June 30, 2017 | -0.30 |
| March 31, 2017 | -0.41 |
| December 31, 2016 | -0.38 |
| September 30, 2016 | -0.38 |
| June 30, 2016 | -0.36 |
| March 31, 2016 | -0.31 |
| December 31, 2015 | -0.12 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.221 |
| Filana Therapeutics, Inc. | -0.2213 |
| CorMedix, Inc. | -0.1877 |
| Eloxx Pharmaceuticals, Inc. | -0.486 |
| Breakthrough Chemistry, Inc. | -0.1113 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -12.88M |
| Revenue (Quarterly) | 259.69M |
| Total Expenses (Quarterly) | 272.57M |
| Enterprise Value | 7.114B |
| Gross Profit Margin (Quarterly) | 91.97% |
| Profit Margin (Quarterly) | -4.96% |
| Earnings Yield | -2.23% |
| Normalized Earnings Yield | -2.358 |